Please ensure Javascript is enabled for purposes of website accessibility

Why Protalix BioTherapeutics Stock Is Plunging Today

By Prosper Junior Bakiny - Apr 28, 2021 at 12:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors did not like the company's latest regulatory update.

What happened?

Shares of Protalix BioTherapeutics (PLX 0.46%) are falling off a cliff on Wednesday after the company announced a disappointing regulatory update regarding one of its pipeline candidates, pegunigalsidase alfa (PRX-102). The biopharmaceutical company's stock was down by 38.4% as of 12:41 p.m. EDT, after dropping by as much as 43.2% earlier in the day.

So what

Pegunigalsidase alfa is an experimental treatment for a rare genetic disorder called Fabry disease. Protalix BioTherapeutics is developing this therapy in collaboration with privately owned Chiesi Global Rare Diseases. Today, the two entities reported that they had received a complete response letter from the U.S. Food and Drug Administration (FDA) for their biologics license application for pegunigalsidase alfa as a treatment for Fabry disease in adult patients.

The FDA sends a complete response letter to communicate it has completed its review of a new or generic drug application, and it decided that it will not approve it for marketing in its present form.

Man holding letter blocks that spell "FDA."

Image source: Getty Images.

It isn't clear why the FDA declined to approve this product; for all investors know, it could be due to potentially severe adverse reactions associated with it, manufacturing issues, or insufficient evidence of its efficacy. Whatever it is, Protalix BioTherapeutics vowed to continue pursuing this project.

CEO Dror Bashan said, "While disappointing, we remain confident in the strength of our data and in the depth of our program. We remain committed to the program and to working with the FDA and Chiesi toward the approval of PRX‑102."

Now what

Regulatory setbacks are always problematic for drugmakers, especially for a relatively small company with limited sources of revenue such as Protalix BioTherapeutics. Thus, it isn't surprising to see investors sell off shares of the healthcare company today. But Protalix BioTherapeutics is planning on giving an update regarding the next step in its attempt to earn FDA approval for pegunigalsidase alfa soon. Unless the company can outline a clear path toward regulatory approval, its shares will likely remain southbound. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Protalix BioTherapeutics, Inc. Stock Quote
Protalix BioTherapeutics, Inc.
$1.09 (0.46%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.